Greater persistence and adherence to basal insulin therapy is associated with lower healthcare utilization and medical costs in patients with type 2 diabetes: a retrospective database analysis

被引:0
|
作者
Aroda, Vanita R. [1 ]
Nielsen, Nick [2 ]
Mangla, Kamal K. [2 ]
Multani, Jasjit [3 ]
Divino, Victoria [3 ]
Namvar, Tarlan [4 ]
Rajpura, Jigar [4 ]
机构
[1] Brigham & Womens Hosp, Endocrinol Diabet & Hypertens, Boston, MA 02115 USA
[2] Novo Nord A S, Bagsvaerd, Denmark
[3] IQVIA Inc, Falls Church, VA USA
[4] Novo Nordisk Inc, Plainsboro, NJ USA
关键词
Patient Compliance; Health Care Costs; Diabetes Mellitus; Type; 2; ECONOMIC OUTCOMES; FOLLOW-UP; MELLITUS; PREDICTORS; MANAGEMENT; PEOPLE; IMPACT; PEN;
D O I
10.1136/bmjdrc-2023-003825
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction We aimed to assess persistence and adherence to basal insulin therapy, their association with all-cause healthcare resource utilization (HCRU) and direct medical costs, and predictors of persistence and adherence in adults with type 2 diabetes.Research design and methods A retrospective cohort study was conducted with US adults with type 2 diabetes initiating basal insulin therapy between January 1, 2016, and December 31, 2018, using IQVIA PharMetrics Plus claims data. Persistence and adherence were assessed during 1 year post-initiation per previous definitions. Demographic/clinical characteristics were assessed during the 1 year pre-initiation. Inverse probability of treatment weighting (IPTW) was used to adjust for confounding variables. Post-IPTW, all-cause HCRU and direct medical costs were assessed during the first-year and second-year post-initiation by persistence and adherence status. Multivariable logistic regression was used to identify predictors of persistence and adherence.Results The final sample comprised 64,953 patients; 56.8% demonstrated persistence and 41.9% demonstrated adherence. Patients demonstrating persistence and adherence were significantly less likely to have a hospitalization than patients demonstrating non-persistence or non-adherence, respectively. In the second-year post-initiation, total mean all-cause direct medical costs per patient were lower for patients demonstrating persistence and significantly lower for patients demonstrating adherence. Prior use of both oral and injectable antidiabetic medication predicted persistence and adherence compared with patients with only prior oral antidiabetic medication use (persistence OR, 1.50 (95% CI, 1.44 to 1.57); adherence OR, 1.48 (95% CI, 1.42 to 1.55)).Conclusions Persistence and adherence to basal insulin was associated with fewer hospitalizations and lower direct medical costs.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Factors and outcomes associated with discontinuation of basal insulin therapy in patients with type 2 diabetes mellitus
    Zhang, Puhong
    Zhang, Heng
    Li, Xian
    Chen, Minyuan
    Wang, Du
    Ji, Linong
    ENDOCRINOLOGY DIABETES & METABOLISM, 2020, 3 (02)
  • [42] Cardiovascular outcomes and healthcare costs of liraglutide versus basal insulin for type 2 diabetes patients at high cardiovascular risk
    Huang, Wan-Chun
    Chen, Yen-Chou
    Wu, Chung-Hsuen
    Ko, Yu
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [43] Cardiovascular outcomes and healthcare costs of liraglutide versus basal insulin for type 2 diabetes patients at high cardiovascular risk
    Wan-Chun Huang
    Yen-Chou Chen
    Chung-Hsuen Wu
    Yu Ko
    Scientific Reports, 11
  • [44] A RETROSPECTIVE DATABASE ANALYSIS OF HEALTHCARE RESOURCE UTILIZATION AND ASSOCIATED COSTS AMONG PATIENT TREATED WITH RUFINAMIDE IN UK
    Varga, S.
    Tsong, W.
    Jenkins-Jones, S.
    Holden, S. E.
    Morgan, C.
    VALUE IN HEALTH, 2018, 21 : S344 - S345
  • [45] Direct medical costs of severe hypoglycaemic events in patients with type 2 diabetes in England: A retrospective database study
    Holbrook, Tim
    Tang, Yuexin
    Das, Romita
    Shankar, R. Ravi
    Tunceli, Kaan
    Williams, Jean
    Radican, Larry
    Holden, Sarah E.
    Morgan, Chris Ll.
    Piercy, James
    Currie, Craig J.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2017, 71 (06)
  • [46] Initiating basal insulin therapy in patients with type 2 diabetes mellitus
    Stoneking, K
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2005, 62 (05) : 510 - 518
  • [47] Basal insulin or premix analogue therapy in type 2 diabetes patients
    Raskin, Philip R.
    Hollander, Priscilla A.
    Lewin, Andrew
    Gabbay, Robert A.
    Bode, Bruce
    Garber, Alan J.
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2007, 18 (01) : 56 - 62
  • [48] Glycemic Control and Adherence to Basal Insulin Therapy in Taiwanese Patients with Type 2 Diabetes (T2D)
    Chien, Ming-Nan
    Chen, Yen-Ling
    Hung, Yi-Jen
    Wang, Shu-Yi
    Lu, Wen-Tsung
    Chen, Chih-Hung
    Lin, Ching-Ling
    Huang, Tze-Pao
    Tsai, Ming-Han
    Tseng, Wei-Kung
    Wu, Ta-Jen
    Ho, Cheng
    Lin, Wen-Yu
    Chen, Bill
    Chuang, Lee-Ming
    DIABETES, 2014, 63 : A600 - A600
  • [49] Persistence with Basal Insulin and Frequency of Hypoglycemia Requiring Hospitalization in Patients with Type 2 Diabetes
    Roussel, Ronan
    Detournay, Bruno
    Boultif, Zahra
    Bahloul, Amar
    Teissier, Clement
    Charbonnel, Bernard
    DIABETES THERAPY, 2020, 11 (08) : 1861 - 1872
  • [50] Persistence with Basal Insulin and Frequency of Hypoglycemia Requiring Hospitalization in Patients with Type 2 Diabetes
    Ronan Roussel
    Bruno Detournay
    Zahra Boultif
    Amar Bahloul
    Clement Teissier
    Bernard Charbonnel
    Diabetes Therapy, 2020, 11 : 1861 - 1872